Recurrent Pyroglutamic Acidosis Related to Therapeutic Acetaminophen

Am J Med Sci. 2018 Apr;355(4):387-389. doi: 10.1016/j.amjms.2017.08.001. Epub 2017 Aug 3.

Abstract

Pyroglutamic acid, an intermediate in glutathione metabolism, can lead to elevated anion gap metabolic acidosis as rare complication of acetaminophen therapy in adults. Acquired pyroglutamic acidosis has been observed primarily in settings associated with glutathione deficiency. Risk factors for glutathione deficiency include critical illness, chronic liver or kidney disease, advanced age, female gender, alcohol abuse, malnutrition, pregnancy, antiepileptic drugs, and chronic acetaminophen use. Diagnosis of pyroglutamic acidosis requires both the exclusion of common etiologies of increased anion gap metabolic acidosis and a high index of suspicion. Treatment involves discontinuation of acetaminophen, supportive care, and addressing risk factors for glutathione deficiency. The current report describes an ambulatory patient with multiple risk factors for glutathione deficiency, who developed recurrent pyroglutamic acidosis due to acetaminophen use with therapeutic blood levels of acetaminophen.

Keywords: 5-oxoproline; Acetaminophen; High anion gap Metabolic acidosis.

Publication types

  • Case Reports

MeSH terms

  • Acetaminophen / adverse effects*
  • Acetaminophen / therapeutic use
  • Acidosis / chemically induced*
  • Acidosis / therapy
  • Acidosis / urine
  • Adult
  • Female
  • Humans
  • Pyrrolidonecarboxylic Acid / urine*
  • Recurrence
  • Treatment Outcome

Substances

  • Acetaminophen
  • Pyrrolidonecarboxylic Acid